β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
US9828410B2 · kind B2 · utility
18Cited by
169References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 7, 2016 |
| Grant date | Nov 28, 2017 |
| Priority date | — |
| Expiry date | Mar 7, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H19/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A compound of the structure:or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.